• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Potential role of adoptively transferred allogeneic WT1-specific CD4+ and CD8+ T lymphocytes for the sustained remission of refractory AML.

作者信息

Kim Y-J, Cho S-G, Lee S, Kim M-S, Kim E-K, Cho B-S, Sohn H-J, Choi H B, Eom K-S, Min C-K, Kim H-J, Kim Y-G, Kim D-W, Lee J-W, Min W-S, Kim C-C, Kim T-G

出版信息

Bone Marrow Transplant. 2010 Mar;45(3):597-9. doi: 10.1038/bmt.2009.191. Epub 2009 Aug 17.

DOI:10.1038/bmt.2009.191
PMID:19684628
Abstract
摘要

相似文献

1
Potential role of adoptively transferred allogeneic WT1-specific CD4+ and CD8+ T lymphocytes for the sustained remission of refractory AML.过继转移的同种异体WT1特异性CD4+和CD8+ T淋巴细胞对难治性急性髓系白血病持续缓解的潜在作用。
Bone Marrow Transplant. 2010 Mar;45(3):597-9. doi: 10.1038/bmt.2009.191. Epub 2009 Aug 17.
2
Clinical grade expansion of CD45RA, CD45RO, and CD62L-positive T-cell lines from HLA-compatible donors: high cytotoxic potential against AML and ALL cells.来自 HLA 相容供体的 CD45RA、CD45RO 和 CD62L 阳性 T 细胞系的临床级扩增：对急性髓系白血病和急性淋巴细胞白血病细胞具有高细胞毒性潜力。
Exp Hematol. 2006 Apr;34(4):475-85. doi: 10.1016/j.exphem.2005.12.012.
3
CD4(+)and CD8(+)T-cell reactions against leukemia-associated- or minor-histocompatibility-antigens in AML-patients after allogeneic SCT.异基因造血干细胞移植后急性髓系白血病患者针对白血病相关或次要组织相容性抗原的CD4(+)和CD8(+)T细胞反应
Immunobiology. 2014 Apr;219(4):247-60. doi: 10.1016/j.imbio.2013.10.008. Epub 2013 Oct 27.
4
Immune responses to WT1 in patients with AML or MDS after chemotherapy and allogeneic stem cell transplantation.化疗和异基因造血干细胞移植后 AML 或 MDS 患者对 WT1 的免疫反应。
Int J Cancer. 2016 Apr 1;138(7):1792-801. doi: 10.1002/ijc.29909. Epub 2015 Nov 27.
5
Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.来自肾母细胞瘤1癌蛋白的肽表位刺激可识别并杀伤人类恶性间皮瘤肿瘤细胞的CD4 +和CD8 + T细胞。
Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4547-55. doi: 10.1158/1078-0432.CCR-07-0708.
6
Infusion of CD4+ donor lymphocytes induces the expansion of CD8+ donor T cells with cytolytic activity directed against recipient hematopoietic cells.输注CD4 +供体淋巴细胞可诱导具有针对受体造血细胞的细胞溶解活性的CD8 +供体T细胞扩增。
Clin Cancer Res. 2002 Jul;8(7):2052-60.
7
Persistence, immune specificity, and functional ability of murine mutant ras epitope-specific CD4(+) and CD8(+) T lymphocytes following in vivo adoptive transfer.体内过继转移后小鼠突变型ras表位特异性CD4(+)和CD8(+) T淋巴细胞的持久性、免疫特异性及功能能力
Cell Immunol. 1999 May 25;194(1):78-89. doi: 10.1006/cimm.1999.1489.
8
"Infectious tolerance" develops after the spontaneous acceptance of Lewis-to-Dark Agouti rat liver transplants.“感染性耐受”在Lewis大鼠到暗褐鼠肝脏移植自发被接受后形成。
Surgery. 2003 Aug;134(2):227-34. doi: 10.1067/msy.2003.226.
9
Allogeneic cell therapy in murine B-cell leukemia (BCL1): 2. The role of non-activated and rIL-2-activated CD4+ and CD8+ T cells in immunotherapy for leukemia.小鼠B细胞白血病（BCL1）中的同种异体细胞疗法：2. 未激活和rIL-2激活的CD4 +和CD8 + T细胞在白血病免疫治疗中的作用。
Cytokines Cell Mol Ther. 1999 Sep;5(3):153-8.
10
Recognition of clonogenic leukemic cells, remission bone marrow and HLA-identical donor bone marrow by CD8+ or CD4+ minor histocompatibility antigen-specific cytotoxic T lymphocytes.通过CD8 +或CD4 +次要组织相容性抗原特异性细胞毒性T淋巴细胞识别克隆性白血病细胞、缓解期骨髓和HLA匹配供体骨髓。
J Clin Invest. 1995 Aug;96(2):877-83. doi: 10.1172/JCI118134.

引用本文的文献

1
Allogeneic Hematopoietic Cell Transplantation and Cellular Therapy.异基因造血细胞移植与细胞治疗
Blood Cell Ther. 2021 Oct 14;4(Spec Edition):S20-S27. doi: 10.31547/bct-2021-014.
2
Antigen-Specific TCR-T Cells for Acute Myeloid Leukemia: State of the Art and Challenges.用于急性髓系白血病的抗原特异性TCR-T细胞：现状与挑战
Front Oncol. 2022 Mar 9;12:787108. doi: 10.3389/fonc.2022.787108. eCollection 2022.
3
Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant.
异基因移植后输注白血病特异性供者 T 细胞治疗 AML/MDS 患者的临床疗效。
Blood. 2021 May 13;137(19):2585-2597. doi: 10.1182/blood.2020009471.
4
Effects of decitabine on allogeneic immune reactions of donor lymphocyte infusion via activation of dendritic cells.地西他滨通过激活树突状细胞对供体淋巴细胞输注的同种异体免疫反应的影响。
Exp Hematol Oncol. 2020 Sep 3;9:22. doi: 10.1186/s40164-020-00178-y. eCollection 2020.
5
Adoptive Cell Therapy for Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia.过继细胞疗法治疗急性髓系白血病和 T 细胞急性淋巴细胞白血病。
Cancer J. 2019 May/Jun;25(3):199-207. doi: 10.1097/PPO.0000000000000376.
6
Post-transplant immunotherapy with WT1-specific CTLs for high-risk acute myelogenous leukemia: a prospective clinical phase I/II trial.采用WT1特异性细胞毒性T淋巴细胞对高危急性髓性白血病进行移植后免疫治疗：一项前瞻性临床I/II期试验。
Bone Marrow Transplant. 2019 Jun;54(6):903-906. doi: 10.1038/s41409-018-0383-2. Epub 2018 Nov 8.
7
[Comparison of the efficacy of decitabine combined with micro-transplantation or priming regimen as consolidation treatment for older patients with acute myeloid leukemia].[地西他滨联合微小移植或预激方案作为老年急性髓系白血病患者巩固治疗的疗效比较]
Zhonghua Xue Ye Xue Za Zhi. 2018 Apr 14;39(4):305-309. doi: 10.3760/cma.j.issn.0253-2727.2018.04.010.
8
High WT1 expression is an early predictor for relapse in patients with acute promyelocytic leukemia in first remission with negative PML-RARa after anthracycline-based chemotherapy: a single-center cohort study.高WT1表达是接受蒽环类药物化疗后初治缓解且PML-RARa阴性的急性早幼粒细胞白血病患者复发的早期预测指标：一项单中心队列研究。
J Hematol Oncol. 2017 Jan 23;10(1):30. doi: 10.1186/s13045-017-0404-4.
9
Identification of molecular and cytogenetic risk factors for unfavorable core-binding factor-positive adult AML with post-remission treatment outcome analysis including transplantation.确定伴有缓解后治疗结果分析（包括移植）的不良核心结合因子阳性成人急性髓系白血病的分子和细胞遗传学危险因素。
Bone Marrow Transplant. 2014 Dec;49(12):1466-74. doi: 10.1038/bmt.2014.180. Epub 2014 Aug 11.
10
Reactivation of Silenced WT1 Transgene by Hypomethylating Agents - Implications for in vitro Modeling of Chemoimmunotherapy.沉默 WT1 转基因的去甲基化剂再激活-对化疗免疫治疗体外模型的影响。
Immune Netw. 2012 Apr;12(2):58-65. doi: 10.4110/in.2012.12.2.58. Epub 2012 Apr 30.